Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China
Jinhong Gong, Qian Wan, Jingjing Shang, Xiaodan Qian, Dan Su, Zhiqiang Sun, Guangjun Liu
Topics & Concepts
MedicinePer capitaGross domestic productOncologyInternal medicineLung cancerChinaEnvironmental healthPopulationEconomicsLawEconomic growthPolitical scienceLung Cancer Research StudiesNeutropenia and Cancer InfectionsPARP inhibition in cancer therapy